NeuroQuest has discovered blood -based immune biomarkers in Alzheimer's and ALS patients. Blood samples measure unique aspects of the immune system that reflect the disease pathology and can be used for diagnosis, prognosis, and monitoring disease progression- a game changing technology for Alzheimer's care. These patented biomarkers may also lead to a better understanding of the mechanism of neurodegenerative disease, leading to improved therapeutics.
NeuroQuest is a portfolio company of Trendlines Medical, based in Misgav, Israel with a development center in Charleston, SC.
Visit www.neuro-quest.com for more information.